Stephen H. Schwartz
Mr. Schwartz is a shareholder of the firm, which he joined in 2007 after fifteen years in New York city. He is admitted in both Pennsylvania and New York.
Charter Oak College, B.S. 1988
University of Pennsylvania, J.D. 1991
Mr. Schwartz is immersed in the firm’s Terrorist Victims Litigation, and travels regularly to Israel, Jordan, England and France. He was formerly with the Antitrust Department at Skadden Arps Slate Meagher & Flom. Mr. Schwartz was one of the lead attorneys in the Stock Exchanges Options Trading Antitrust Litigation (S.D.N.Y.), the Relafen Antitrust Litigation (D. Mass.), the Contact Lens Antitrust Litigation (M.D. Fla.), and the Old Country Buffets Securities Fraud Litigation (D. Minn.) He also played major roles in the Terazosin Hydrochloride Antitrust Litigation (S.D. Fla.), the Nasdaq Market Makers Antitrust Litigation (S.D.N.Y.), the Brand Name Drug Antitrust Litigation (N.D. Ill.), the Computer Associates Derivative Litigation (Del. Chancery), and the Salomon Inc. Shareholders' Derivative Litigation (S.D.N.Y.).
Representative opinions: In re Terazosin Hydrochloride Antitrust Litigation, 220 F.R.D. 672 (S.D. Fla. 2004)(class certification), In re Stock Exchanges Options Trading Antitrust Litigation, 317 F.3d 134 (2d Cir. 2003) (implied repeal of Sherman Act by Securities Exchange Act, federal jurisdiction), In re Stock Exchanges Options Trading Antitrust Litigation, 171 F. Supp.2d 174 (S.D.N.Y. 2001)(Motion to alter or amend a judgment), In re Terazosin Hydrochloride Antitrust Litigation, 164 F. Supp.2d 1340 (S.D. Fla. 2000)(Per se treatment of restraint of trade), Bristol Hotel Management v. Aetna Casualty & Surety Co., 20 F. Supp.2d 1345 (S.D. Fla. 1998)(RICO), Guice v. Charles Schwab & Co., 651 N.Y.S.2d 352 (N.Y. Ct. App. 1996) (Preemption of state law by Securities Exchange Act).